Biosimilars significantly reduce health care costs in Australia, enhancing access to biologics while driving price competition in the pharmaceutical market. The economic impact of biosimilars on the ...

A study reveals that switching from Humira to Amgevita for IBD maintains disease control and offers significant cost savings.